Pharmacogenetic Approach for Cancer Treatment-Tailored Medicine in Practice

:  This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is cli...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2006-11, Vol.1086 (1), p.223-232
Main Authors: HASEGAWA, YOSHINORI, ANDO, YUICHI, ANDO, MAKI, HASHIMOTO, NAOZUMI, IMAIZUMI, KAZUYOSHI, SHIMOKATA, KAORU
Format: Article
Language:English
Subjects:
Alleles
Antineoplastic Agents, Phytogenic - administration & dosage
Antineoplastic Agents, Phytogenic - adverse effects
Antineoplastic Agents, Phytogenic - therapeutic use
Camptothecin - administration & dosage
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Camptothecin - therapeutic use
chemotherapy
gene polymorphism
Glucuronosyltransferase - antagonists & inhibitors
Glucuronosyltransferase - genetics
Glucuronosyltransferase - physiology
Homozygote
Humans
irinotecan
Neoplasms - drug therapy
Neoplasms - enzymology
Neoplasms - genetics
Pharmacogenetics
Polymorphism, Genetic
UGT1A1
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary::  This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is clinically useful and important for predicting and avoiding related toxicities. On the basis of these backgrounds, the irinotecan label was updated in 2005 in the United States to provide pharmacogenetic information, and a dose reduction of irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele when administered in combination with other agents or a single agent. The irinotecan/UGT1A1 issue and the development of molecular diagnostic testing are now to be translated into clinical practice.
ISSN:0077-8923
1749-6632
DOI:10.1196/annals.1377.020